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Abstract
The emergence of carbapenemases in Enterobacteriaceae has raised global concern among the scientiﬁc, medical and public health
communities. Both the CDC and the WHO consider carbapenem-resistant Enterobacteriaceae (CRE) to constitute a signiﬁcant threat that
necessitates immediate action. In this article, we review the challenges faced by laboratory workers, infection prevention specialists and
clinicians who are confronted with this emerging infection control issue.
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Introduction
When Kumarasamy et al. [1] published the ﬁrst epidemiolog-
ical report on the emergence of Enterobacteriaceae producing a
new carbapenemase (New Delhi metallo-b-lactamase-1
(NDM-1)) in India, Pakistan and the UK in 2010, the impact
on the medical and public health authorities was probably
underestimated. Previously, other carbapenemases had been
described in Enterobacteriaceae, the most clinically important
being KPC, VIM, and IMP. However, since 2010 and the
description of NDM-1, >975 articles related to carbapene-
mases, their mechanisms of action, epidemiology and treat-
ment have been indexed in PubMed. The emergence of
carbapenemases in Enterobacteriaceae has caused global con-
cern among the scientiﬁc, medical and public health commu-
nities [2–11]. Both the CDC and the WHO consider
carbapenem-resistant Enterobacteriaceae (CRE) to constitute
a signiﬁcant threat that necessitates immediate action [12,13].
In this article, we review the challenges faced by laboratory
workers, infection prevention specialists and clinicians who are
confronted with this emerging infection control issue.
CRE constitute a signiﬁcant emerging threat to the public
health and medical communities. Between 2001 and 2011, the
National Nosocomial Infection Surveillance System/National
Healthcare Safety Network data revealed that carbapenem
resistance had increased ten-fold, from 1.6% to 10.4% in
Klebsiella isolates, and four-fold, from 1.2% to 4.2%, in
Enterobacter isolates. Even more concerning in the USA is
that approximately 4% of acute-care hospitals but 18% of
long-term acute-care hospitals (LTACHs) reported at least
one CRE infection in the ﬁrst half of 2012 (CDC website:
http://www.cdc.gov/vitalsigns/hai/cre/). Of particular note is
that production of carbapenemases is one of the mechanisms
conferring resistance to carbapenems among Enterobacteria-
ceae. Once the CLSI lowered the interpretive breakpoints for
carbapenems in 2010, a concomitant and anticipated increase
in the proportion of reported CRE (including expanded-
spectrum b-lactamase or AmpC hyperproducers combined
with porin loss) that were not carbapenemase producers was
seen. Furthermore, although antimicrobial testing is widely
available in the usual clinical laboratory setting, phenotypic and
genotypic testing to detect the presence of carbapenemases in
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CRE is often lacking. For infection prevention specialists, these
organisms are associated with high rates of morbidity and
mortality [5], and, because of carbapenem resistance, thera-
peutic choices are extremely limited. For this reason, stopping
their transmission should be a common goal.
Carbapenemases are most often located on genetic
elements such as plasmids, which are mobile and can be easily
shared among Enterobacteriaceae. Klebsiella pneumoniae carba-
penemase (KPC) emerged in the USA in 2001, and is still the
most common carbapenemase reported. Among the carbape-
nem-resistant K. pneumoniae strains recently reported from 14
hospitals in New York City, 29% were KPC producers [14].
Carbapenem resistance among invasive K. pneumoniae strains
increased in many countries between 2005 and 2011, accord-
ing to the European CDC report: ﬁve countries (Greece,
Cyprus, Italy, Hungary, and Portugal) reported rates of CRE of
>1%, as opposed to only two (Greece and Germany) in 2005
[15]. This interactive database provides up-to-date information
on antimicrobial resistance in different European countries
(www.ecdc.europa.eu/en/healthtopics/antimicrobial_resis-
tance/database/Pages/database.aspx.) KPCs have also been
described in Asia, initially in China in 2004 and then in South
Korea, Taiwan, and Singapore, and community acquisition is
suspected [16].
However, beginning in 2009, several isolates carrying
metallo-b-lactamases such as NDM, VIM and IMP have been
documented in the USA, and are often imported from other
countries. Although KPCs are endemic in some hospitals in the
Mid-Atlantic USA, many of the metallo-b-lactamases have been
isolated from patients who have received healthcare in other
countries. Endemicity of NDM-1 in India was supported by
data demonstrating that bacteria harbouring this enzyme were
present in seepage and drinking water in New Delhi [17]. Few
data are available from clinical settings in many parts of the
world, because there is no well-deﬁned national surveillance
programme. NDM-1 distribution in the community in Singa-
pore was also recently suggested, as it was found in 23% of all
CRE isolates that revealed wide genetic diversity and no
epidemiological link to other known endemic areas [16].
Finally, the worldwide spread of NDM-1 was recently
reviewed and effectively presented by the use of interactive
mapping [18].
Why Infection Prevention Matters
The plasmid carrying the gene encoding the carbapenemase
enzyme also harbours other resistance genes, making
Enterobacteriaceae potentially resistant to almost all of the
antimicrobials included in our armamentarium [19]. Without
existing appropriate treatment for patients, high rates of
morbidity and mortality have been documented in different
studies, reaching 70% in some of them, with an attributable
mortality for bacteraemia of 50% [20]. Additionally, prolonged
hospital stays and increased healthcare costs have been
reported for CRE infections [19]. Moreover, Enterobacteria-
ceae (Escherichia coli in particular) cause most human infections,
and the mortality rate is higher when resistance to multiple
drugs is present [5]. Given the fact that limited therapeutic
agents are available, good infection prevention practices
(beginning with standard precautions that should always be
emphasized as the cornerstone to prevent transmission) are
the primary methods for stemming the spread of CRE in the
healthcare setting (Table 1). Outbreaks involving these highly
resistant microrganisms can result in several deaths and
extensive disruption at a given institution until they can be
contained.
Risk factors for colonization and/or infection with CRE
mirror those previously associated with other multi-
drug-resistant organisms (Fig. 1). The risks of colonization
and infection have been associated with critical illness and
surgery, comorbid conditions, including organ or stem cell
transplantation, the presence of a wound, the use of invasive
devices or mechanical ventilation, and previous use of
antimicrobials (including cephalosporins, carbapenems, and
ﬂuoroquinolones). Additionally, the risk of CRE colonization
increases with: (i) an intensive-care unit stay; (ii) sharing a
room with a known carrier of a CRE strain; (iii) being
transferred between facilities or units; or (iv) prolonged
hospitalization [21–28]. Of those colonized with a CRE strain,
almost one in ten will subsequently show growth of the
organism in a clinical sample [24]. Some of the risks can be
minimized by the use of appropriate infection prevention
practices.
TABLE 1. Infection prevention and antimicrobial steward-
ship recommendations published to prevent the spread of
carbapenem-resistant Enterobacteriaceae
Required infection prevention measures
Implement a surveillance programme to identify potential carriers (screening)
Use contact isolation precautions for colonized and infected patients
Cohort colonized and infected patients
Enhance hand hygiene and support with audits
Increase the frequency of environmental cleaning
Limit the use of devices and remove unnecessary devices
Implement antimicrobial stewardship, including a programme
Educate healthcare workers about critical prevention measures
Suggested enhanced infection prevention measures
Limit patient transfers
One-to-one nursing
Decolonize patients with chlorhexidine gluconate baths
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Worldwide, authorities have published guidance for labora-
tories and infection prevention specialists to better manage
CRE (including NDM, VIM, IMP and KPC producers) [19,25].
Schwaber and Carmeli also reported the Israeli experience and
the strategies implemented when the government had to
contain a decade-long but rapid spread of KPC-producing
Enterobacteriaceae [20]. Bundled interventions are required to
control CRE transmission. Hand hygiene and standard
precautions remain the cornerstone of the prevention strat-
egies. The use of surveillance cultures to identify unrecognized
carriers, contact precautions and isolation with or without
cohorting of patients and staff, enhanced antimicrobial stew-
ardship to prevent the emergence of resistance and enhanced
environmental cleaning are all viewed as important and are
reviewed here. All of these interventions require educated
healthcare workers, and have been recommended to control
the spread of other multidrug-resistant organisms. The
recommended practices are extrapolated from information
about other Gram-negative bacteria, past experience, and the
magnitude of resistance. These recommendations have been
effective in outbreak settings, although additional supporting
evidence is needed in endemic situations. Additional infection
prevention practices that seem to be relevant to carbapenem-
ase producers merit our attention, and include the screening of
travellers, because of the risk of colonization or infection
associated with global travel, immigration, and medical tourism,
and high-risk healthcare facilities such as long-term-care
facilities.
Identifying Carriers: Epidemiological
Surveys and Screening Cultures
Expert panels have identiﬁed key elements to prevent the
spread of CRE. One of the primary mechanisms is to act
pro-actively and survey for those at risk of being colonized or
infected, and some recommend that we should pre-emptively
isolate high-risk individuals with contact precautions [9].
Studies have found that patients asymptomatically colonized
with CRE constitute a reservoir for transmission of the
pathogen to others, highlighting the importance of timely
detection [29]. Screening activities can be developed that
reﬂect the epidemiology of the setting, depending on whether
the institution has a low prevalence or no known cases of CRE,
or whether it is located in an endemic area [13]. In institutions
with a low prevalence, public health authorities worldwide
have recommended the initial use of epidemiological surveys
(screening with rectal swabs sent for culture) to identify
high-risk patients, including those returning from endemic
areas who were hospitalized while abroad or who have been
transferred from a healthcare facility where the prevalence is
high [13,30,31]. For example, nurses screen patients in the
emergency department or at admission by asking about travel
or hospitalization abroad or in endemic institutions during the
last year. This early initial evaluation may be essential in
low-prevalence areas, given that there are insufﬁcient data at
this point to recommend active surveillance cultures for all
admitted patients in that setting [30].
On the other hand, based on recent ﬁndings, institutions
with a high prevalence, located in endemic areas or facing an
outbreak situation should strongly consider active screening of
all patients deemed to be at risk, including those previously
colonized or infected, and pre-emptively isolating them with
contact precautions. The Israeli Ministry of Health imple-
mented this strategy to control the spread of CRE among all:
(i) ward contacts of patients growing CRE; (ii) patients
transferred from another hospital; and (iii) patients housed in
wards with a high prevalence in the previous months [20].
Various reports support several practices when a hospital
identiﬁes an outbreak. The ﬁrst is to identify whether there
has been spread by culturing contacts of cases and to maintain
surveillance cultures for at least 2 weeks after the last carrier
has been discharged from the hospital [32]. Second, random
point-prevalence surveys on previously affected units are also
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FIG. 1. A schematic of risk factors
associated with carbapenem-resistant
Enterobacteriaceae colonization, infection,
or both. Those in italics are potentially
preventable with appropriate infection
control or antimicrobial stewardship.
COPD, chronic obstructive pulmonary
disease; ICU, intensive-care unit.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 854–861
856 Clinical Microbiology and Infection, Volume 20 Number 9, September 2014 CMI
advised [32]. On the basis of several guidelines, the rectal site
(reﬂecting the colonic content) is most commonly screened
for CRE [13,30,31,33]. Other frequently colonized sites that
can be cultured include urine, wounds, throat or nares, groin,
and catheters. As yet, there has been no systematic compar-
ative study performed to identify the most efﬁcacious site to
screen for carbapenemase-producing organisms. One recent
study determined that the rectum was the single most
sensitive site for detection of KPC producers (sensitivity of
88%), and adding an inguinal skin swab increased the sensitivity
to 100% [34].
Detecting gastrointestinal carriers is challenging, and several
different screening protocols and types of medium are
employed in clinical laboratories. The choice of method
should be dictated by the associated costs and the technical
skills required. Recommendations vary, and examples include
plating the screening specimen on a selective medium (includ-
ing MacConkey) with previous overnight incubation in selec-
tive enrichment broth containing a carbapenem disk (usually
meropenem) [35]; the sensitivity and speciﬁcity range from
47% to 99% and from 10% to 86%, respectively [36,37]. A new
medium, SUPERCARBA, was speciﬁcally developed to detect
carbapenemase producers among Enterobacteriaceae with a
sensitivity and speciﬁcity of 96% and 82%, respectively; also, it
seems to be easier to use in the clinical laboratory [38,39].
Colorimetric agars have also been used for screening
carbapenemase producers, with varying sensitivity and
speciﬁcity, depending on the medium used and the carbape-
nemase enzyme involved (range: 40–97% for sensitivity and
6–100% for speciﬁcity) [36,37,39,40]. A new chromogenic
medium, chromID Carba (bioMerieux, Lyon, France), designed
speciﬁcally for the screening of carbapenemase producers,
has a sensitivity of 91–100% and a speciﬁcity of 76–97%
[36,37,41].
Finally, molecular testing is emerging as a powerful
technology, and was used in the Israeli national screening
programme as the reference standard for CRE detection. It is
noteworthy that, according to the Israeli experience, 15% of
patients with a CRE identiﬁed by PCR had negative cultures
with traditional techniques [20]. The higher sensitivity of PCR
is notable, but it comes with higher costs and requires
technical skills that are not available in every clinical laboratory.
If it is performed in a reference laboratory, the delays make it
impractical for infection control purposes. Furthermore, PCR
may suffer from a lower speciﬁcity, which can be seen with the
detection of carbapenemase genes in bacteria other than
Enterobacteriaceae (NDM-1 can be recovered from Acinetobac-
ter species or Pseudomonas species, for example). On the other
hand, PCR is considered to be the preferred method for
conﬁrming the CRE resistance mechanism in Enterobacteriaceae
[42]. Recently published data have shown that matrix-assisted
laser desorption ionization time-of-ﬂight mass spectrometry is
also a powerful, rapid and cost-effective way of conﬁrming the
presence of most carbapenemases in Enterobacteriaceae
[43,44].
Preventing Transmission: Contact Isolation
and Cohorting
For these highly resistant organisms, the use of contact
precautions and single rooms is recommended. With
multiple cases or an outbreak setting, physical separation
of non-carriers, those at high risk of colonization/infection
until the results of rectal screening at admission are known
(pre-emptive contact isolation) and those found to be
colonized or infected with CRE is commonly used, and
contributes to controlling the outbreak situations
[13,19,20,25,30,31,45]. Both contact isolation and this co-
horting have been shown to limit the number of secondary
cases and control outbreaks in different settings [9,46].
Furthermore, several studies have reported an additional
measure that includes cohorting the nursing staff to prevent
cross-transmission [8,25]. In 2007, several hospitals in Israel
implemented this measure to stem the spread of CRE in
acute-care hospitals [20].
The duration of isolation for those colonized or infected by
CRE is unknown. The mean duration of excretion of CRE
associated with gastrointestinal colonization varies signiﬁcantly
between 9.8 days and 19 days, and depends on the carbape-
nemase enzyme isolated in Enterobacteriaceae. One study
found a median carriage time of 3 months [25], but prolonged
excretion for up to 1 year has been documented [24,47–50].
Schechner et al. [24] documented three factors associated
with persistent carriage: ﬂuoroquinolone use, intra-facility
transfer, and re-admission within 3 months of a culture
growing CRE. Feldman et al. conducted a prospective cohort
study of 125 patients with positive KPC screening test results.
Three-quarters remained positive when tested within 30 days
of the ﬁrst positive test result, but <30% were still positive
after 6 months. The persistence of positive screening cultures
was associated with the presence of any catheter, low
functional status, recent acquisition (<4 months), and stay in
a long-term-care facility. Recent antimicrobial use was not
associated with persistent carriage in this study, but a high
proportion of patients in both groups had been recently
exposed to antimicrobials [51]. For all of these reasons, and
because good data on the number of tests required to conﬁrm
clearance are still lacking, many recommend that isolation be
maintained until hospital discharge [19].
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Protecting Patients: Hand Hygiene
Hand hygiene remains the key intervention to prevent
transmission. Guidelines on CRE prevention from the CDC,
Health Protection Agency, Health Canada and others all
recommend strict hand hygiene for all staff and visitors
entering and leaving the patient’s room. Compliance with hand
hygiene practices is of paramount importance to prevent CRE
transmission. Furthermore, with a mathematical model, the
transmission dynamics of carbapenemase-producing K. pneu-
moniae in a surgical unit in Greece showed that the minimum
hand hygiene compliance rate needed to control the trans-
mission of these bacteria was 50% [46]. According to these
data, hand hygiene seems to be the single most important
measure to control transmission.
Other sources of indirect transmission of CRE have been
reported, including contaminated endoscopes or ventilators
[27]. In most of the outbreaks reported that were related to
endoscopy, insufﬁcient reprocessing was the main reason for
nosocomial transmission [52].
Preventing CRE Emergence: Antimicrobial
Stewardship
The causal relationship between antimicrobial misuse and the
emergence of antimicrobial-resistant pathogens is well docu-
mented, and supports the need for antimicrobial stewardship
programmes to limit the development of resistance among
bacteria (including Enterobacteriaceae) [53]. Good data on the
real impact of antimicrobial stewardship programmes on the
development or persistence of CRE colonization or infection
are still lacking and, at times, the data are controversial.
Different antimicrobial agents have been associated with an
increased risk of CRE colonization in past studies, so many
experts advocate decreasing antimicrobial consumption in
general instead of targeting speciﬁc agents on the basis of these
data [24,25,54,55]. As previously mentioned, not all studies
have shown a link between antimicrobial exposure and an
increased risk of colonization [51]. However, more data on
the beneﬁts of antimicrobial stewardship programmes for CRE
development are needed.
Environment Cleaning
Although several studies have found low rates of recovery of
CRE in the environment [34,49,56], contamination of the
environment has been suspected in some outbreaks, and this
has led to the recommendation of frequent cleaning of
environmental surfaces (especially high-touch surfaces). The
use of dedicated material to avoid indirect transmission via
fomites to non-carriers is prudent, and extensive, enhanced
cleaning has been used in different outbreaks [19,32,45].
The efﬁcacy of new and adjuvant environment cleaning
technologies is yet to be studied for multidrug-resistant
Gram-negative bacteria, including CRE; however, Passaretti
et al. [57] demonstrated a reduction (although not statistically
signiﬁcant) in the acquisition of multidrug-resistant Gram
negative bacteria with vaporized hydrogen peroxide disinfec-
tion of the environment. This technology was used for
additional disinfection after terminal cleaning in other settings
where CRE were reported [32,45].
Infection Control in Hospitals with Limited
Resources
Most of the infection control strategies presented in this
review were studied and implemented in hospitals located in
high-income or medium-income countries, and might not be
possible or sustainable in hospitals with limited resources. For
these institutions, standard precautions with strict hand
hygiene and auditing of compliance should be taken at all
times. Epidemiological questionnaires to identify those at risk
of being colonized (e.g. transferred from an endemic institu-
tion, area, or country) might be implemented to enhance
case-ﬁnding. Targeting the most at-risk patients in the hospital
(in intensive-care or oncology units, or those exposed to
wide-spectrum antimicrobials and invasive devices) can also
enhance resource utilization. The use of contact precautions
(gown and gloves) when caring for a known carrier will also
decrease transmission, and, in some settings, cohorting may be
a practical solution.
Other (enhanced) Infection Control
Measures
Other infection prevention strategies have also been used in
different outbreaks to control the spread of CRE, but their
effectiveness is still unclear. Education of healthcare personnel
is part of outbreak management [25]. In 2011, in a KPC-pro-
ducing K. pneumoniae outbreak that involved 18 patients (11 of
whom died), universal gowns and gloves were utilized by all
staff members and visitors on the affected intensive-care unit.
Also, visiting was restricted [32]. Decolonization of patients by
the use of daily chlorhexidine bathing was reported by
Munoz-Price et al. [58] as part of a bundled intervention plan
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to control an outbreak of KPC-producing Klebsiella species in a
long-term-care facility, and was found to be successful.
The Importance of Long-term-care Facilities
and Travel for CRE Acquisition
Two speciﬁc situations have been associated with an increased
risk of CRE colonization, and differentiate our approach to
CRE prevention and control from the practices related to
other multidrug-resistant bacteria, especially Gram-negative
bacteria. In the USA, several reports have associated LTACHs
with high rates of CRE colonization and a high risk of
transmission within the facility. This dynamic creates a
continuous inﬂux of colonized patients into acute-care
hospitals [58–63]. Although the prevalence varies according
to the geographical area surveyed, it can reach up to 54% [61].
The extensive network of exposure and the relationships
between LTACHs, nursing homes and acute-care hospitals
were nicely shown by Won et al. [64], using molecular
epidemiological methods following an outbreak of KPC-pro-
ducing Enterobacteriaceae. These studies support the need for
integrated regional, if not national, approaches to CRE
prevention, open channels of communication between
institutions, and enhanced infection control policies in
long-term-care facilities.
Travel to endemic countries is associated with the impor-
tation of carbapenemase-producing Enterobacteriaceae into
non-endemic settings, and was demonstrated vividly with
one of these enzymes (NDM-1) following its description in
India a few years ago. The introduction of NDM-1 to the UK
was described in the ﬁrst epidemiological study published on
the then new resistance mechanism. The authors reported
that 60% of the affected patients had travelled to India or
Pakistan within 1 year, and many had been hospitalized abroad
for medical emergencies or elective cosmetic surgery [1].
Since then, many reports have highlighted the importance of
international travel (including tourism, medical tourism, and
hospitalization abroad) as a potential source of carbapenem-
ase-producing Enterobacteriaceae cases and outbreaks
[9,42,65,66]. Furthermore, not all single cases reported can
be epidemiologically linked to endemic regions, and a group of
researchers from France hypothesized potential cross-trans-
mission from healthcare workers, who can also become
colonized when travelling abroad [67]; however, this merits
further assessment. It is important for those who have been
hospitalized in a foreign country with a high prevalence to be
targeted ﬁrst for screening and pre-emptive isolation. Again,
this challenges the infection prevention specialist, as targeting
those at risk is made even more difﬁcult by the number of
people travelling around the world yearly who could be
potential carriers.
Conclusion
CRE constitute an emerging threat and a worldwide concern.
Given the limited antimicrobial therapy available at this point,
infection prevention remains the primary opportunity that we
have to stem the spread of these worrying organisms.
Prevention strategies for these organisms are similar to those
for other resistant microorganisms, and include hand hygiene,
surveillance cultures, the use of barrier precautions and
isolation, aggressive environmental cleaning, and, sometimes,
enhanced measures. Most importantly, infection control
practices are usually bundled, and should be tailored to the
situation and available resources. Laboratory procedures have
been reﬁned recently, and require speciﬁc methods to identify
organisms. Finally, it is paramount to act pro-actively and
develop regional or national approaches to prevent transmis-
sion. Reporting of data and national surveillance are critical to
help stem the spread of CRE.
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